Clinical trials
Terminated Fatigue trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
64 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 5 |
| 2010 | 3 |
| 2011 | 8 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 64 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 6 |
| Wake Forest University Health Sciences | 4 |
| Massachusetts General Hospital | 3 |
| Case Comprehensive Cancer Center | 2 |
| Forest Laboratories | 2 |
| Icahn School of Medicine at Mount Sinai | 2 |
| Mayo Clinic | 2 |
| National Institute of Nursing Research (NINR) | 2 |
| National Institutes of Health Clinical Center (CC) | 2 |
| OHSU Knight Cancer Institute | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fatigue | 64 |
| Breast Neoplasms | 9 |
| Neoplasms | 6 |
| Pain | 5 |
| Anxiety Disorders | 4 |
| Fibromyalgia | 4 |
| Multiple Sclerosis | 4 |
| Sleep Initiation and Maintenance Disorders | 4 |
| Inflammation | 3 |
| Anemia | 2 |
Trials
Showing 1 to 25 of 64. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.